Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.37 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.37 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.37 |
| ▸ | DDB1 known ✓ | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN known ✓ | Q96SW2 | 1/20 | 0.37 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.36 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.36 |
| ▸ | AVPR1A known ✓ | P37288 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939227 | 0.99 | ALDH1A1 (0.41) | ALDH1A1MAP1LC3BCA12CA9KMT2A | |
| SCHEMBL4940264 | 0.89 | DDB1 (0.44) | ALDH1A1MAP1LC3BKMT2AHPGDHSD17B10 | |
| SCHEMBL4936723 | 0.88 | DDB1 (0.45) | ALDH1A1MAP1LC3BKMT2AKDM4EMAPT | |
| SCHEMBL4938575 | 0.88 | DDB1 (0.44) | ALDH1A1MAP1LC3BKMT2AKDM4EMAPT | |
| SCHEMBL4936120 | 0.88 | CRBN (0.43) | ALDH1A1MAP1LC3BKMT2AGAAHSD17B10 | |
| SCHEMBL4933646 | 0.87 | DDB1 (0.45) | MAP1LC3BKMT2AMAPTDDB1CRBN | |
| SCHEMBL4937867 | 0.86 | CRBN (0.43) | ALDH1A1MAP1LC3BKMT2AGAAHSD17B10 | |
| SCHEMBL4929916 | 0.86 | CRBN (0.48) | ALDH1A1MAP1LC3BCA12CA9KDM4E | |
| SCHEMBL4938809 | 0.86 | DDB1 (0.41) | ALDH1A1MAP1LC3BKDM4EDDB1CRBN | |
| Glycine SCHEMBL4929867 | 0.85 | DDB1 (0.41) | ALDH1A1MAP1LC3BCA12CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10406147-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2019-09-10 | — | — | US | disclosed |
| US-20190247383-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| US-10166222-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20180050025-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2018-02-22 | — | — | US | disclosed |
| US-9669015-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2017-06-06 | — | — | US | disclosed |
| US-20150272940-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-9085563-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-07-21 | — | — | US | disclosed |
| US-20140179737-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-8637545-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2014-01-28 | — | — | US | disclosed |
| EP-1867649-B1 | PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2012-12-12 | — | — | EP | disclosed |
| US-20080051432-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2008-02-28 | — | — | US | disclosed |
| EP-1867649-A1 | PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050025-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF9, TNFRSF1A, NGFR | GAA 4304/4885CHRM2 143/4885OPRM1 65/4885 |
| US-10406147-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TNF, TNFRSF1A, TNFRSF9 | GAA 4349/4885CHRM2 154/4885OPRM1 119/4885 |
| US-10166222-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TNFRSF1A, TNFRSF9, NGFR | GAA 4251/4885CHRM2 135/4885OPRM1 67/4885 |
| US-20150272940-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, TNFRSF9 | GAA 4349/4885CHRM2 154/4885OPRM1 119/4885 |
| US-20190247383-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, TNFRSF9 | GAA 4340/4885CHRM2 183/4885OPRM1 94/4885 |
| US-20080051432-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, TNFRSF9 | GAA 4349/4885CHRM2 154/4885OPRM1 119/4885 |
| US-20140179737-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, TNFRSF9 | GAA 4349/4885CHRM2 154/4885OPRM1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.